艾伯维,作为昔日药王的拥有者,面临专利悬崖压境,举起拳头挥向新战场!自免领域并购提速、神经科学重金押注、ADC赛道连出重拳,艾伯维以一场战略大突围,向市场宣告:断腕求生,只为更凶猛的进攻。01深陷泥潭艾伯维近年来深陷多重危机,修美乐(阿达木单抗)作为艾伯维的“现金牛”,曾连续十一年蝉联全球药品销售冠军,累计销售额超2000亿美元。然而,随着其在主流市场的专利保护陆续到期,生物类似药的冲击导致其收入...
Source Link艾伯维,作为昔日药王的拥有者,面临专利悬崖压境,举起拳头挥向新战场!自免领域并购提速、神经科学重金押注、ADC赛道连出重拳,艾伯维以一场战略大突围,向市场宣告:断腕求生,只为更凶猛的进攻。01深陷泥潭艾伯维近年来深陷多重危机,修美乐(阿达木单抗)作为艾伯维的“现金牛”,曾连续十一年蝉联全球药品销售冠军,累计销售额超2000亿美元。然而,随着其在主流市场的专利保护陆续到期,生物类似药的冲击导致其收入...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.